NCT03400709View on ClinicalTrials.gov

Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

November 30, 2017

Conditions
Cisplatin Adverse ReactionHearing Loss Ototoxic
Interventions
DRUG

N Acetylcysteine

Oral administration of drug, before, during and after Chemoradiotherapy including Cisplatin.

DRUG

Placebo Oral Tablet

Placebo treatment

Trial Locations (1)

7160166

Daniel Munoz, Santiago

All Listed Sponsors
lead

Hospital San Juan de Dios, Santiago

OTHER

NCT03400709 - Protective Role of N-acetylcisteine From Cisplatin-induced Ototoxicity in Patients With Head and Neck Cancer | Biotech Hunter | Biotech Hunter